PT - JOURNAL ARTICLE AU - Junwu, Wang AU - Pengzhi, Shi AU - Dong, Chen AU - Shuguang, Wang AU - Pingchuan, Wang AU - Xinmin, Feng AU - Liang, Zhang TI - The safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-associated pneumonia: a systematic review and meta-analysis AID - 10.1101/2021.07.01.21259838 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.01.21259838 4099 - http://medrxiv.org/content/early/2021/07/02/2021.07.01.21259838.short 4100 - http://medrxiv.org/content/early/2021/07/02/2021.07.01.21259838.full AB - Mesenchymal stem cells (MSCs) therapy is considered one of the most promising treatments in the context of the coronavirus disease 2019 (COVID-19) pandemic. However, the safety and effectiveness of MSCs in the treatment of COVID-19-associated pneumonia patients need to be systematically reviewed and analyzed. Two independent researchers searched for the relevant studies published between October 2019 and April 2021 in PubMed, Embase, Cochrane Library, WAN FANG, and CNKI databases. A total of 22 studies involving 371 patients were included in the present study. MSCs were administered in 247 participants, and MSCs were allogeneic from umbilical cord, adipose tissue, menstrual blood, placenta, Wharton’s jelly, or unreported sources. Combined results found that MSCs group significantly reduced the incidence of adverse events (OR = 0.43, 95%CI. = 0.22∼0.84, P = 0.01) and mortality (OR = 0.17, 95%CI. = 0.06∼0.49, P < 0.01), and the difference compared with control group was statistically significant. No MSCs treat-related serious adverse events were reported. The lung function and radiographic outcomes, and biomarker levels of inflammation and immunity all showed improvement trends. Therefore, MSCs therapy is an effective and safe method in the treatment of COVID-19-associated pneumonia and shows advantages in less adverse events and mortality. However, a standard and effective MSCs treatment program needs to be developed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Jiangsu Provincial Medical Youth Talent [grant number QNRC2016342]; Project on Maternal and Child Health Talents of Jiangsu Province [grant number F201801]; and Six Talent Peaks Project in Jiangsu Province [grant number LGY2019035]. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article and its supplementary information files.